Print
|
Close
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Active:
Yes
Cancer Type:
Prostate Cancer
NCT ID:
NCT04221542
Trial Phases:
Phase I
Protocol IDs:
20180146 (primary)
NCI-2020-00424
2021-005052-11
2023-504361-23
Eligibility:
18 Years and older, Male
Study Type:
Treatment
Study Sponsor:
Amgen, Inc.
NCI Full Details:
http://clinicaltrials.gov/show/NCT04221542
Summary
Evaluate the safety and tolerability of AMG 509 in adult participants and determine the
maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
Treatment Sites in Georgia
Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.